CN101443340B - 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法 - Google Patents

前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法 Download PDF

Info

Publication number
CN101443340B
CN101443340B CN2007800176204A CN200780017620A CN101443340B CN 101443340 B CN101443340 B CN 101443340B CN 2007800176204 A CN2007800176204 A CN 2007800176204A CN 200780017620 A CN200780017620 A CN 200780017620A CN 101443340 B CN101443340 B CN 101443340B
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800176204A
Other languages
English (en)
Chinese (zh)
Other versions
CN101443340A (zh
Inventor
克利夫·伯克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of CN101443340A publication Critical patent/CN101443340A/zh
Application granted granted Critical
Publication of CN101443340B publication Critical patent/CN101443340B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
CN2007800176204A 2006-03-14 2007-03-14 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法 Active CN101443340B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78221106P 2006-03-14 2006-03-14
US60/782,211 2006-03-14
PCT/US2007/064002 WO2007106869A1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Publications (2)

Publication Number Publication Date
CN101443340A CN101443340A (zh) 2009-05-27
CN101443340B true CN101443340B (zh) 2013-12-04

Family

ID=38229662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800176204A Active CN101443340B (zh) 2006-03-14 2007-03-14 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法

Country Status (9)

Country Link
US (3) US7696185B2 (https=)
EP (1) EP1999136B1 (https=)
JP (1) JP2009532338A (https=)
CN (1) CN101443340B (https=)
AU (1) AU2007226542B2 (https=)
CA (1) CA2645809C (https=)
ES (1) ES2397973T3 (https=)
PL (1) PL1999136T3 (https=)
WO (1) WO2007106869A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700234T3 (es) 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010149666A1 (en) * 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP5657902B2 (ja) * 2010-03-17 2015-01-21 株式会社コスモステクニカルセンター ポリオキシアルキレンステロールエーテル誘導体及び／又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
US9328129B2 (en) * 2010-11-12 2016-05-03 Washington State University Peptidomimetic inhibitors of PSMA
WO2012174136A1 (en) * 2011-06-15 2012-12-20 Cancer Targeted Technology Llc Chelated psma inhibitors
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
PL2970345T3 (pl) * 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2842578B1 (en) 2013-08-27 2018-06-27 GILUPI GmbH Diagnostic device for the detection of biomarkers
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US10383912B2 (en) * 2014-08-18 2019-08-20 Washington State University Tunable pH-sensitive linker for controlled drug release
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
IL287989B2 (en) * 2019-05-13 2025-07-01 Bracco Imaging Spa Modified cyanine dyes and their conjugates
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
CN111675747B (zh) * 2020-07-30 2021-04-27 中国医学科学院医药生物技术研究所 抗肿瘤药物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110723A1 (en) * 2001-02-07 2004-06-10 Frangioni John V. Modified psma ligands and uses related thereto
CN1537170A (zh) * 2000-11-20 2004-10-13 ����ҽѧԺ 定量检测前列腺特异性膜抗原和其它前列腺标记的方法和装置
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US782211A (en) 1904-05-23 1905-02-07 George W Sturgis Vending-wagon.
RU2218179C2 (ru) * 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1537170A (zh) * 2000-11-20 2004-10-13 ����ҽѧԺ 定量检测前列腺特异性膜抗原和其它前列腺标记的方法和装置
US20040110723A1 (en) * 2001-02-07 2004-06-10 Frangioni John V. Modified psma ligands and uses related thereto
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体

Also Published As

Publication number Publication date
JP2009532338A (ja) 2009-09-10
US7696185B2 (en) 2010-04-13
AU2007226542B2 (en) 2013-08-22
US20070219165A1 (en) 2007-09-20
CN101443340A (zh) 2009-05-27
US8293725B2 (en) 2012-10-23
EP1999136B1 (en) 2012-10-24
USRE42275E1 (en) 2011-04-05
EP1999136A1 (en) 2008-12-10
PL1999136T3 (pl) 2013-03-29
WO2007106869A1 (en) 2007-09-20
CA2645809C (en) 2015-05-26
US20100183517A1 (en) 2010-07-22
CA2645809A1 (en) 2007-09-20
AU2007226542A1 (en) 2007-09-20
ES2397973T3 (es) 2013-03-12

Similar Documents

Publication Publication Date Title
CN101443340B (zh) 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
CA2449054C (en) Integrin targeting liposome for nucleic acid delivery
Lattuada et al. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents
JP2021073272A (ja) 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
US9861702B2 (en) Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
JP6840148B2 (ja) 造影剤
JP2006523237A (ja) Ｐｉ−３キナーゼインヒビタープロドラッグ
JP2006523237A5 (https=)
HUP9902636A2 (hu) NAALADáz inhibtor hatású foszfinil-származékok és ezeket tartalmazó gyógyszerkészítmények
WO2009070302A1 (en) Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
US11414455B2 (en) Toll-like receptor 2 ligands and methods of making and using thereof
US20090011975A1 (en) Targeted bone marrow protection agents
HUP0301711A2 (hu) Elágazó láncú lipofil molekulák származékai és alkalmazásuk
EP2691402B1 (fr) Derives d'acide hydroxybisphosphonique bifonctionnels
EP1343758A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
IL145210A (en) Use of pmbc in the preparation of an agent for the selective binding of cells, a method for the detection of apoptosis and a pharmaceutical composition for the treatment of a disease characterized by the presence of apoptosis in cells, tissues or cellular structures
US20060210479A1 (en) Targeting chelants and chelates
CN101410139A (zh) 施陶丁格连接在生物活性化合物的体内组装中的用途
CA2356777A1 (fr) Composes pseudopeptidiques dotes d'une activite inhibitrice a l'egard des voies activees par les proteines a activite tyrosine kinase et les compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant